LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

LifeVantage (LFVN) announced the results of a third-party cell study on the synergistic impact of Protandim Nrf2 Synergizer ...

As previously reported, Craig-Hallum initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Interest in weight loss ...

LifeVantage Corporation (Nasdaq: LFVN), a leader in cellular activation of optimal health processes, today announced the results of a groundbreaking third-party cell study on the synergistic impact of ...

As the U.S. stock market navigates a mixed landscape with the S&P 500 inching higher and tech stocks experiencing volatility, investors are keenly observing growth companies with substantial insider ...

Havas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world. The ad agency is pitching the series as both a science-led initiative ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...